Voxelotor for the treatment of sickle cell disease

M Vissa, E Vichinsky - Expert Review of Hematology, 2021 - Taylor & Francis
Introduction: The clinical manifestations of sickle cell disease (SCD) result from an inherited
mutation in the beta-globin chain of hemoglobin (Hb) that causes Hb tetramers to polymerize …
被引用次数：19 相关文章

Voxelotor for the treatment of sickle cell disease.

M Vissa, E Vichinsky - Expert Review of Hematology, 2021 - europepmc.org
Introduction: The clinical manifestations of sickle cell disease (SCD) result from an inherited
mutation in the beta-globin chain of hemoglobin (Hb) that causes Hb tetramers to polymerize …

Voxelotor for the treatment of sickle cell disease

M Vissa, E Vichinsky - Expert review of hematology, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction: The clinical manifestations of sickle cell disease (SCD) result from an inherited
mutation in the beta-globin chain of hemoglobin (Hb) that causes Hb tetramers to polymerize …
[PDF] researchgate.net

[PDF][PDF] Voxelotor for the treatment of sickle cell disease

M Vissa, E Vichinsky - 2021 - researchgate.net
Introduction: The clinical manifestations of sickle cell disease (SCD) result from an inherited
mutation in the beta-globin chain of hemoglobin (Hb) that causes Hb tetramers to polymerize …